SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

1349

CNE1000000W4

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
2.08 ^HKD	0.00%		-1.42%	-18.43%

Apr. 01	Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	MT
Mar. 28	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	CI

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 26 August 2022

March 28, 2022 at 07:40 am EDT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. proposed final dividend of RMB 0.07 per share for the year ended 31 December 2021, payable on 26 August 2022. Ex-dividend date 05 July 2022 and Record date 12 July 2022.

Latest news about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	Mar. 31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	Mar. 28	CI
Fudan-Zhangjiang Bio's 2023 Profit Falls	Feb. 26	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	Jan. 04	MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	Jan. 03	MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	Dec. 27	MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	Dec. 18	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	Dec. 18	CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	Nov. 13	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	Nov. 13	CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	Nov. 08	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	Nov. 08	CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	23-10-31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23-10-23	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	23-10-20	CI
Fudan-Zhangjiang Bio Puchases Structured Deposit Products	23-10-12	MT
Fudan-Zhangjiang Bio Swings to Profit in H1	23-08-11	MT
Fudan-Zhangjiang Bio Enrolls First Patient in FZ-AD004 Clinical Trial	23-08-10	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors	23-08-09	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-02	CI
Fudan-Zhangjiang Bio to Swing to H1 Profit	23-07-18	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-07-18	CI
Fudan-Zhangjiang Bio Subscribes for 356 Million Yuan of Ping An Bank’s Structured Deposit Products	23-07-04	MT

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

More charts

Company Profile

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.	-18.43%	782M
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-15.94%	4.8B
YUHAN CORPORATION	+1.89%	3.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+18.47%	3.72B
INDIVIOR PLC	+26.16%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.63%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-29.37%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+2.55%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals